Issue 119 • June 2022 How ambitious are the emissions targets of pharma and biotech companies? CMO agreements need to go public, but ‘glib’ onshoring not the answer Should Covid-19 clinical trial plans still centre around EUAs? In association with Continuous manufacturing cautiously builds on hype Covid-19 and a drive for sustainability back the move to continuous manufacturing, but large-scale investment drags In association with 06/01/2022 15:03:01
